Legend Biotech announced first-in-human clinical data for LB2102, its investigational DLL3-targeted CAR-T cell therapy for patients with relapsed or refractory small cell lung cancer (SCLC) or large-cell neuroendocrine carcinoma (LCNEC) — cancers with very limited treatment options and poor outcomes.
Presented at ASCO 2026, the early phase 1 results demonstrate evidence of clinical activity and a manageable safety profile. At higher dose levels, an objective response rate of 28.6% and disease control rate of 78.6% were observed, including durable responses in some heavily pretreated patients.
LB2102 is an investigational DLL3-targeted autologous CAR-T cell therapy with dnTGFBR2 Armor engineered to enhance activity by overcoming immunosuppressive signaling within the tumor microenvironment.
The therapy is part of Legend Biotech's effort to expand CAR-T beyond blood cancers and into solid tumors. Under a 2023 licensing agreement, Novartis holds exclusive worldwide rights to develop, manufacture, and commercialize Legend's DLL3-targeted CAR-T therapies, including LB2102. Legend is conducting the ongoing phase 1 U.S. trial, while Novartis oversees all other development, manufacturing, and commercialization activities.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!